Free Trial
→ Elon's next millionaires start October 24? (From Behind the Markets) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
$4.63
-7.0%		$5.28
$2.87
▼
$6.45
$399.42M0.39292,950 shs414,459 shs
GLAS
Glass House Brands
$3.66
-5.0%		$7.92
$3.55
▼
$13.93
$357.10MN/A1.89 million shs1.62 million shs
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
$3.93
-3.0%		$5.05
$3.88
▼
$13.15
$402.76M0.851.41 million shs1.73 million shs
Vaxart, Inc. stock logo
VXRT
Vaxart
$0.46
+0.2%		$0.49
$0.31
▼
$0.84
$111.27M1.05263,885 shs217,910 shs
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-0.99%-1.78%-6.21%+2.47%+60.13%
GLAS
Glass House Brands
-5.88%-25.81%-51.54%-65.03%+382,399,900.00%
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
-3.11%-5.81%-14.92%-46.36%-62.95%
Vaxart, Inc. stock logo
VXRT
Vaxart
+3.80%+4.65%-5.86%-13.85%+34.61%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
$4.63
-7.0%		$5.28
$2.87
▼
$6.45
$399.42M0.39292,950 shs414,459 shs
GLAS
Glass House Brands
$3.66
-5.0%		$7.92
$3.55
▼
$13.93
$357.10MN/A1.89 million shs1.62 million shs
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
$3.93
-3.0%		$5.05
$3.88
▼
$13.15
$402.76M0.851.41 million shs1.73 million shs
Vaxart, Inc. stock logo
VXRT
Vaxart
$0.46
+0.2%		$0.49
$0.31
▼
$0.84
$111.27M1.05263,885 shs217,910 shs
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-0.99%-1.78%-6.21%+2.47%+60.13%
GLAS
Glass House Brands
-5.88%-25.81%-51.54%-65.03%+382,399,900.00%
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
-3.11%-5.81%-14.92%-46.36%-62.95%
Vaxart, Inc. stock logo
VXRT
Vaxart
+3.80%+4.65%-5.86%-13.85%+34.61%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
2.33
Hold$7.0051.19% Upside
GLAS
Glass House Brands
2.00
Hold$16.00337.40% Upside
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
2.50
Moderate Buy$25.00536.13% Upside
Vaxart, Inc. stock logo
VXRT
Vaxart
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

Latest VXRT, SPRY, AVIR, and GLAS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/11/2026
GLAS
Glass House Brands
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D+) ➝ Sell (D)
9/8/2026
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access to unlock brokerage rankings
Set Price Target$15.00
8/20/2026
GLAS
Glass House Brands
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeStrong-Buy ➝ Hold
8/17/2026
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
8/14/2026
GLAS
Glass House Brands
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Set Price Target$15.00
8/13/2026
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetEqual Weight$6.00 ➝ $7.00
7/17/2026
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/AN/AN/AN/A$3.53 per shareN/A
GLAS
Glass House Brands
$181.98M1.86N/AN/AN/A∞
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
$84.28M4.64N/AN/A$1.16 per share3.39
Vaxart, Inc. stock logo
VXRT
Vaxart
$237.26M0.47$0.11 per share4.30$0.37 per share1.24
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-$158.35M-$2.08N/AN/AN/AN/A-64.25%-57.12%11/11/2026 (Estimated)
GLAS
Glass House Brands
-$29.66MN/AN/A18.29N/A-31.68%-60.92%-15.69%N/A
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
-$171.30M-$2.18N/AN/AN/A-184.24%-256.67%-69.63%11/9/2026 (Estimated)
Vaxart, Inc. stock logo
VXRT
Vaxart
$16.33M$0.162.86N/AN/A15.88%53.04%20.85%11/12/2026 (Estimated)

Latest VXRT, SPRY, AVIR, and GLAS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/11/2026Q3 2026
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-$0.51N/AN/AN/A$50.45 millionN/A
11/9/2026Q3 2026
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
-$0.33N/AN/AN/A$42.84 millionN/A
8/13/2026Q2 2026
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
-$0.4777-$0.63-$0.1523-$0.63$31.32 million$33.66 million
8/12/2026Q2 2026
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-$0.5550-$0.41+$0.1450-$0.41$33.03 millionN/A
8/6/2026Q2 2026
Vaxart, Inc. stock logo
VXRT
Vaxart
-$0.12-$0.06+$0.06-$0.06$26.21 million$27.19 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/AN/AN/AN/AN/A
GLAS
Glass House Brands
N/AN/AN/AN/AN/A
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
N/AN/AN/AN/AN/A
Vaxart, Inc. stock logo
VXRT
Vaxart
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/A
8.13
8.13
GLAS
Glass House Brands
0.77
1.33
0.70
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
13.72
3.48
3.28
Vaxart, Inc. stock logo
VXRT
Vaxart
N/A
1.60
1.60

Institutional Ownership

CompanyInstitutional Ownership
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
86.67%
GLAS
Glass House Brands
N/A
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
68.16%
Vaxart, Inc. stock logo
VXRT
Vaxart
18.05%

Insider Ownership

CompanyInsider Ownership
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
21.60%
GLAS
Glass House Brands
N/A
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
33.80%
Vaxart, Inc. stock logo
VXRT
Vaxart
2.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
5580.21 million62.88 millionOptionable
GLAS
Glass House Brands
35792.75 millionN/AN/A
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
20099.45 million65.83 millionOptionable
Vaxart, Inc. stock logo
VXRT
Vaxart
65243.70 million236.88 millionNo Data

Recent News About These Companies

Analyzing Vaxart (OTCMKTS:VXRT) and Contineum Therapeutics (NASDAQ:CTNM)
October 13 at 8:17 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31115357
Vaxart (OTCMKTS:VXRT) Stock Price Crosses Below 200 Day Moving Average - Should You Sell?
October 9, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31102161
Vaxart's VXA-H5-02 Shows 100% Survival In H5N1 Ferret Study
October 8, 2026  |  rttnews.comhttps://www.rttnews.com/3697590/vaxart-s-vxa-h5-02-shows-100-survival-in-h5n1-ferret-study.aspx
Vaxart Announces Publication of Preclinical Study Demonstrating 100% Protection Against a Lethal Dose of H5N1 Avian Flu in a Ferret Challenge Model
October 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vaxart-announces-publication-preclinical-study-124000090.html
Vaxart Announces Publication of Preclinical Study Demonstrating 100% Protection Against a Lethal Dose of H5N1 Avian Flu in a Ferret Challenge Model
October 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/08/3377292/25416/en/vaxart-announces-publication-of-preclinical-study-demonstrating-100-protection-against-a-lethal-dose-of-h5n1-avian-flu-in-a-ferret-challenge-model.html
Vaxart Highlights Oral Vaccine Platform, COVID Trial Progress at H.C. Wainwright Conference
September 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/event-vaxart-highlights-oral-vaccine-platform-covid-trial-progress-at-hc-wainwright-conference-2026-09-15/
Vaxart to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vaxart-present-h-c-wainwright-120000773.html
Vaxart to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/08/3357576/25416/en/vaxart-to-present-at-the-h-c-wainwright-28th-annual-global-investment-conference.html
Vaxart Secures New European Patent Covering Oral Norovirus Vaccine Technology
August 27, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vaxart-secures-european-patent-covering-213754366.html
Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology
August 26, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/26/3351686/25416/en/vaxart-expands-intellectual-property-portfolio-with-european-patent-protecting-proprietary-norovirus-vaccine-technology.html
Vaxart Inc (VXRT) (Q2 2026) Earnings Call Highlights: Oral COVID Vaccine Shows Promise, Cash ...
August 10, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vaxart-inc-vxrt-q2-2026-010727416.html
Vaxart outlines Phase IIb COVID-19 top line data in first half of 2027 backed by BARDA funding
August 8, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4629637-vaxart-outlines-phase-iib-covidminus-19-top-line-data-in-first-half-of-2027-backed-by-barda
Vaxart, Inc. (VXRT) Q2 2026 Earnings Call Transcript
August 7, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4933620-vaxart-inc-vxrt-q2-2026-earnings-call-transcript
Vaxart Provides Business Update and Reports Second Quarter 2026 Financial Results
August 6, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vaxart-provides-business-update-and-reports-second-quarter-2026-financial-results-1036422626
Vaxart Q2 2026 earnings preview
August 5, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/vaxart-q2-2026-earnings-preview/ar-AA29sE4e
Vaxart to Host Stockholder Fireside Chat on August 7 at 4:30 p.m. ET
July 30, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vaxart-host-stockholder-fireside-chat-120000165.html
Vaxart to Host Stockholder Fireside Chat on August 7 at 4:30 p.m. ET
July 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/30/3335990/25416/en/vaxart-to-host-stockholder-fireside-chat-on-august-7-at-4-30-p-m-et.html
Vaxart to Participate in BTIG Biotechnology Conference 2026
July 21, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vaxart-participate-btig-biotechnology-conference-120000945.html
Vaxart to Participate in BTIG Biotechnology Conference 2026
July 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/21/3330405/25416/en/vaxart-to-participate-in-btig-biotechnology-conference-2026.html
Vaxart Announces Results of Annual Meeting of Stockholders
July 17, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vaxart-announces-results-annual-meeting-200500981.html
Vaxart Announces Results of Annual Meeting of Stockholders
July 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/17/3329278/25416/en/vaxart-announces-results-of-annual-meeting-of-stockholders.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Atea Pharmaceuticals stock logo

Atea Pharmaceuticals NASDAQ:AVIR

$4.63 -0.35 (-7.03%)
Closing price 04:00 PM Eastern
Extended Trading
$4.64 +0.00 (+0.11%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Glass House Brands NYSE:GLAS

$3.66 -0.19 (-4.99%)
Closing price 03:59 PM Eastern
Extended Trading
$3.66 +0.01 (+0.19%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Glass House Brands is a vertically integrated cannabis company. Glass House Brands is based in LONG BEACH, Calif.

ARS Pharmaceuticals stock logo

ARS Pharmaceuticals NASDAQ:SPRY

$3.93 -0.12 (-2.96%)
Closing price 04:00 PM Eastern
Extended Trading
$3.87 -0.06 (-1.60%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Vaxart stock logo

Vaxart OTCMKTS:VXRT

$0.46 +0.00 (+0.20%)
As of 03:49 PM Eastern

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas